Catalyst

Slingshot members are tracking this event:

Roche's (RHHBY) Rituxan Designated a Breakthrough Therapy by FDA for Pemphigus Vulgaris, a Rare Autoimmune Skin Disorder

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
RHHBY

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 24, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Rituxan, Fda, Pemphigus Vulgaris, Breakthrough Therapy